Macular degeneration
This article was originally published in The Gray Sheet
Executive Summary
Medicare Coverage Advisory Committee will convene Sept. 9 to review the current national non-coverage policy for ocular photodynamic therapy with verteporfin for age-related macular degeneration patients with occult and no classic subfoveal choroidal neovascularization as determined by a fluorescein angiogram. 1CMS review of the policy was announced July 25, pursuant to a May 27 settlement CMS reached with the American Council for the Blind and American Association of People with Disabilities in Washington, D.C. federal court (2"The Gray Sheet" June 2, 2003, p. 7). The suit was filed against CMS in August 2002...